OCZ-401

OCZ-401 is a potent, highly selective, small-molecule inhibitor of the KRAS G12C mutation, developed by Jiangsu Carephar Pharmaceutical for the treatment of advanced solid tumors. The drug functions by covalently and irreversibly binding to the cysteine residue at position 12 of the KRAS protein, effectively locking it in an inactive GDP-bound state. This mechanism prevents the activation of downstream oncogenic signaling pathways, such as the MAPK/ERK pathway, which are critical for the proliferation and survival of cancer cells harboring this specific mutation. OCZ-401 received Investigational New Drug (IND) clearance in China in 2021 and from the U.S. FDA in 2022, subsequently entering Phase 1 clinical trials to evaluate its safety and efficacy in patients with KRAS G12C-mutated cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer.